GlassScriptPhysician profile
Ali H Moussa
NPI 1548207814
$4,785.27
in general payments reported to CMS, 2019-2025
51 companies · $690 in 2025
The $690 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $390 · 2021: $423 · 2022: $885 · 2023: $1,255 · 2024: $540 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.31 |
| Education | $442.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $844.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $496.49 | 2019-2025 | Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $407.09 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $306.41 | 2020-2025 | Enhertu |
| Gilead Sciences, INC. | $160.44 | 2019-2023 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $156.74 | 2022-2023 | Imbruvica, Epkinly |
| Seagen INC. | $152.26 | 2020-2023 | Adcetris |
| Aveo Pharmaceuticals, INC. | $140.10 | 2023-2024 | Fotivda |
| Celgene Corporation | $123.40 | 2021-2023 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $118.67 | 2020-2025 | Vyloy, Padcev |
| Beigene USA, INC. | $115.82 | 2023-2024 | Brukinsa |
| Sirtex Medical INC | $114.26 | 2023 | Sir-Spheres Microspheres |
| Amgen INC. | $113.81 | 2019-2022 | |
| Lilly USA, LLC | $101.05 | 2019-2024 | Jaypirca |
| Novartis Pharmaceuticals Corporation | $95.90 | 2023-2025 |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Moussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.